200 related articles for article (PubMed ID: 28748602)
1. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
Setty BA; Stanek JR; Mascarenhas L; Miller A; Bagatell R; Okcu F; Nicholls L; Lysecki D; Gupta AA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748602
[TBL] [Abstract][Full Text] [Related]
2. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
5. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
[TBL] [Abstract][Full Text] [Related]
6. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
7. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
[TBL] [Abstract][Full Text] [Related]
8. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy in patients with refractory Ewing sarcoma].
Raciborska A; Bilska K; Drabko K; Rogowska E; Chaber R; Pogorzała M; Wyrobek E; Połczyńska K; Rodriguez-Galindo C; Woźniak W
Med Wieku Rozwoj; 2013; 17(2):117-25. PubMed ID: 23988368
[TBL] [Abstract][Full Text] [Related]
12. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Gruber ML; Buster WP
Am J Clin Oncol; 2004 Feb; 27(1):33-8. PubMed ID: 14758131
[TBL] [Abstract][Full Text] [Related]
14. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Hernández-Marqués C; Lassaletta-Atienza A; Ruiz Hernández A; Blumenfeld Olivares JA; Arce Abaitua B; Cormenzana Carpio M; Madero Lopez L
An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
[TBL] [Abstract][Full Text] [Related]
15. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
Venkatramani R; Malogolowkin MH; Mascarenhas L
Pediatr Blood Cancer; 2014 Apr; 61(4):756-9. PubMed ID: 24115645
[TBL] [Abstract][Full Text] [Related]
19. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
20. Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma.
Mixon BA; Eckrich MJ; Lowas S; Engel ME
J Pediatr Hematol Oncol; 2013 May; 35(4):e163-6. PubMed ID: 22735885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
